We’ve heard about some great innovations in treatment of prostate cancer – but of course early detection is essential in providing better outcomes for men with prostate cancer. This year sees a new Policy Paper from EAU on PSA Screening. Following the first White Paper on Prostate Cancer on lower risk and mortality rate of Prostate Cancer, the European Association of Urology (EAU) has initiated a second Policy Paper addressing the need to reconsider structured population-based PSA screening for prostate cancer. In close conjunction with medical experts, representatives from related medical societies and patient advocacy group this Policy Paper was prepared, covering key topics such as the latest evidence, consequences of not performing PSA screening, overdiagnosis & overtreatment, and six recommendations as a call to action. Prof Hein Van Poppel talks us through it.

свернуть